Category: Abbott LaboratoriesSyndicate content

Medtech's top stent-makers land SharedClarity contracts

July 29, 2014 by Arezu Sarvestani

Healthcare-provider alliance SharedClarity signs some of medtech's biggest firms to land specialized pricing for peripheral stents.

Medtech's top stent-makers land SharedClarity contracts

Four of medtech's biggest firms agreed to offer peripheral stents at specialized prices to members of SharedClarity, an organization formed through the alliance of some of the country's largest health insurance and care providers.

Abbott CEO chides critics of corporate inversions | Medtech Wall Street news for the week of July 21, 2014

July 24, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Allergan cuts 1,500 jobs, faces SEC complaint; A countdown to failure for Valeant's hostile $53B Allergan takeover; GE Healthcare idles for another quarter

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott CEO defends inversions amid corporate exodus furor

JNJ looks to bolster "subscale" cardiovascular business | The week in medtech M&A

July 23, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter

Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere

July 16, 2014 by Brad Perriello

YYmeta

Medtronic-Covidien merger may get caught in anti-inversion legislation | Medtech legal news for the week of July 21, 2014

July 21, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

July 16, 2014 by Arezu Sarvestani

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

Abbott raises full-year guidance on strong Q2, but medtech lags

July 18, 2014 by Arezu Sarvestani

Abbott Labs reports a strong 2nd quarter driven in large part by diagnostics, but the medical device segment took a hit in U.S. sales, leading to a pretty flat quarter.

Abbott raises full-year guidance, but medtech numbers fail to impress

Illinois-based Abbott (NYSE:ABT) released a 2nd-quarter earnings report showing some strong momentum, but the healthcare giant's medical device sector didn't fare so well.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.

Abbott CEO defends inversions amid corporate exodus furor

Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014

July 17, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Ocular Therapeutix sets terms for IPO; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B; Exo-suit maker ReWalk files for $57.5M IPO; Intersect ENT sets terms for $65M IPO

Ocular Therapeutix sets terms for IPO

July 11, 2014 by Brad Perriello

Ocular Therapeutix sets terms for IPO
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp